NEWS
ROCHE LAUNCHES NEW ANALYTICAL UNITS FOR DELIVERING GREATER EFFICIENCY AND CAPACITY TO LABORATORIES
Roche has announced the launch of its new analytical units , cobas c 703 and cobas ISE neo , for the cobas pro integrated solutions , in countries accepting the CE mark . The cobas pro integrated solutions is a scalable and modular diagnostic platform designed for high-volume laboratories . These analytical units offer ‘ cutting-edge ’ features to help address some of the key challenges faced by diagnostic laboratories worldwide such as shortage of qualified staff and space limitations . clinical chemistry and immunochemistry platform , the cobas pro integrated solutions , to the next level . By integrating high-volume clinical chemistry testing and increased automation , we will set a new standard for high volume testing in the clinical lab .”
With cobas pro integrated solutions , the required sample volume per test has been reduced on average by 43 % compared to previous generation systems . Additionally , the plastic generated per test result has been reduced by up to 78 % due to smaller reagent pack sizes and a higher number of tests per pack .
Designed to seamlessly integrate into clinical chemistry and immunochemistry testing , Roche ’ s innovative mass spectrometry analyser will also be available as part of the cobas pro integrated solutions in the near future .
“ Today more than ever , accurate and timely diagnostics is critical for effective delivery of healthcare . Labs are under increasing pressure to process more samples , at greater speed without compromising on accuracy ,” said Matt Sause , CEO of Roche Diagnostics . “ With the launch of the cobas c 703 and cobas ISE neo , we are taking our latest generation
EXPERT GIVES WARNING IN DIAGNOSTIC GAPS IN WOMEN ’ S HEALTH WITH MENSTRUAL INSIGHTS BEING IGNORED
In a panel discussion diving into the diagnostics landscape for women ’ s health , key leaders involved shared their messages on the failings and shortcomings in the sector . In the panel event hosted at HLTH Europe , titled : ‘ Mind the gap : Why diagnostic disparities damage women ’ s health ’, experts highlighted the importance of early prevention , value-based care and leveraging innovative diagnostic tools like menstrual blood .
Sara Naseri , Co-founder and CEO of Qvin , discussed the untapped potential of menstrual blood in diagnostics . Throughout the talk , she exclaimed passionately about the failures of society and industry in shaming and hiding such a powerful tool . She left an interesting final message to audiences : “ I think it ’ s important to remember that it wasn ’ t until the 1990s that women were even included in medical research and not until recently that female voters were included in drug development . As a field , within healthcare , Women ’ s Health is just behind , and we have to catch up .
“ We need to look for where women have an advantage . We believe that advantage is the block that we ’ ve been going up every month , that could in fact be a way to accelerate the participation or visitation in clinical research and actually close the gender data gap . We are making strides in really starting to break down the barriers in realising that a period is not a waste product , and in fact , an incredible opportunity .”
www . intelligenthealth . tech 9